This spontaneous report as received from a nurse practitioner refers to her currently 16 years old daughter. The patient historical therapies included Multivitamin (unspecified), Omega-3 and high doses (not specified) of vitamin D (unspecified). The patient's historical conditions included generalized lymphadenopathy, platelet level dropped, abnormal platelet function, dropped level of platelets, petechiae, nose bleeds, bruising, profuse itching and very large urticaria on her thigh after vaccination with VARIVAX (merck) in 2008 (Described in MARRS # 1403USA007226). The patient's brother experienced very high fever, generalized lymphadenopathy and neurologic symptoms which included repetitive motions and sensory issues where he could not tolerate any normal sound and became very sensitive to touch after vaccination with VARIVAX (merck) in 2008 (Described in MARRS # 1403USA007224). The reporter stated that both her son (Described in MARRS # 1403USA007225) and daughter received a dose of GARDASIL and both experienced severe reactions. The patient received the first dose of GARDASIL (dose, strength, route and site of administration not reported) in July 2013 and after the first dose, on an unknown date in 2013, her daughter, who had normal regular period for last 3 years, noticed that her period had become very light after GARDASIL dose. The patient also experienced muscle spasm and Paresthesia in September 2013 and continued to experience very light menstrual period following first GARDASIL dose. The patient received a second dose of GARDASIL (dose, strength, route and site of administration not reported) in October 2013 along with flu vaccine (name unspecified but manufactured by Sanofi Pasteur) (dose, strength, route and site of administration not reported) and her menstrual period completely stopped and experienced amenorrhea (date not provided) after receiving second dose of GARDASIL. The patient was seen by reproductive endocrinologist (date not provided) for amenorrhea and it was found that the patient had very low ovarian reserve and Anti-mullerian hormone (AMH) level (dates not provided). The endocrinologist who examined the patient told to the reporter that the patient experienced sudden ovarian insufficiency which was heading toward total ovarian failure. The endocrinologist mentioned to nurse practitioner of two girls who experienced ovarian failure that endocrinologist read in unspecified newspaper article and explained to nurse practitioner that her daughter's case was similar to that of newspaper article (Described in MARRS # 1403USA007228). The patient was tested last Monday (03-MAR-2014, also reported as 10-MAR-2014) for platelet function and level of platelet continued to be low. The reporter stated her children were very sensitive to vaccines and she was closely working with allergist and immunologist to find the cause for these reactions and she also mentioned that level of alum presented in GARDASIL might be linked to these symptoms. Follow up information was received from nurse practitioner. The reporter called back to provide further information regarding symptoms that her daughter experienced following her second administration of GARDASIL (unspecified date, also reported that second dose was received in October 2013). The reporter stated that the patient experienced depigmentation of her skin on her arms and face immediately following the administration of GARDASIL. The patient also was diagnosed with Raynaud's disease (blue fingers and toes) and experienced severe joint and muscle achiness following the administration of GARDASIL. The relatedness between events and suspect therapy was not reported. This is one of two same patient cases from the same source (second case MARRS # 1403USA007226). This is one of several cases from the same source (other cases MARRS # 1403USA007224, 1403USA007225, 1403USA003195, 1403USA007226, 1403USA007228). Additional information is not expected.